EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)

Emre Bilgin iD, Tuba Demirci Yıldırım, Bahar Özdemir Ulusoy, Tahir Saygın Öğüt, Murat Karabacak, Öznur Sadioğlu Çağdaş, Reşit Yıldırım, Deniz Can Güven, Cansu Akleylek, Elif Ediboğlu, Muhammet Emin Kutu, Duygu Özgür und 27 weitere

Internal and Emergency Medicine · 2024

DOI: 10.1007/s11739-024-03577-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Internal and Emergency Medicine, 2024. Verfasst von Emre Bilgin und 38 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hacettepe University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate cancer incidence in patients with ANCA-associated vasculitis (AAV), compare it with the age/sex-specific cancer risk of the Turkish population, and explore independent risk factors associated with cancer. This multicenter, incidence case–control study was conducted using the TRVaS registry. AAV patients without cancer history before AAV diagnosis were included. Demographic and AAV-related data of patients with and without an incident cancer were compared. Standardized cancer incidence rates were calculated using age-/sex-specific 2017 Turkish National Cancer Registry data for cancers (excluding non-melanoma skin cancers). Cox regression was performed to find factors related to incident cancers in AAV patients. Of 461 AAV patients (236 [51.2%] male), 19 had incident cancers after 2022.8 patient-years follow-up. Median (IQR) disease duration was 3.4 (5.5) years, and 58 (12.6%) patients died [7 with cancer and one without cancer (log-rank, p = 0.04)]. Cancer-diagnosed patients were older, mostly male, and more likely to have anti-PR3-ANCA positivity. The cumulative cyclophosphamide dose was similar in patients with and without cancer. Overall cancer risk in AAV was 2.1 (SIR) ((1.3–3.2), p = 0.004); lung and head-neck [primary target sites for AAV] cancers were the most common. In Cox regression, male sex and ≥ 60 years of age at AAV diagnosis were associated with increased cancer risk, while receiving rituximab was associated with decreased cancer risk. Cancer risk was 2.1 times higher in AAV patients than the age-/sex-specific cancer risk of the Turkish population population, despite a high rate of rituximab use and lower dose of cyclophosphamide doses. Vigilance in cancer screening for AAV patients covering lung, genitourinary, and head–neck regions, particularly in males and the elderly, is vital.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNeoplasmsHumansMaleFemaleTurkeyMiddle AgedCase-Control StudiesAgedIncidenceRisk FactorsRegistriesAdult

Stichwörter der Autor:innen

ANCA-associated vasculitisCancerCyclophosphamideGranulomatous polyangiitisHead–neck cancersLung cancerRituximab

Autor:innen und Institutionen

  • Faculty of Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.
  • Hacettepe Vasculitis Research Center, Ankara, Turkey.
  • Faculty of Medicine, Division of Rheumatology, Dokuz Eylul University, İzmir, Turkey.
  • Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.
  • Faculty of Medicine, Division of Rheumatology, Akdeniz University, Antalya, Turkey.
  • Faculty of Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey.

ORCID-Profile: Emre Bilgin

Förderung

  • Hacettepe University

Zitieren

APA

Bilgin, E., Demirci Yıldırım, T., Özdemir Ulusoy, B., Öğüt, T. S., Karabacak, M., Sadioğlu Çağdaş, Ö., Yıldırım, R., Güven, D. C., Akleylek, C., Ediboğlu, E., Kutu, M. E., Özgür, D., Kardaş, R. C., Bölek, E. Ç., Sandal Uzun, G., Özsoy, Z., Sarıyıldız, E., Ayan, G., Armağan, B., …, & Karadağ, Ö. (2024). Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS). Internal and Emergency Medicine. https://doi.org/10.1007/s11739-024-03577-9

Vancouver

Bilgin E, Demirci Yıldırım T, Özdemir Ulusoy B, Öğüt TS, Karabacak M, Sadioğlu Çağdaş Ö, et al. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS). Internal and Emergency Medicine. 2024. doi:10.1007/s11739-024-03577-9

BibTeX
@article{Bilgin2024,
  author = {Bilgin, Emre and Demirci Yıldırım, Tuba and Özdemir Ulusoy, Bahar and Öğüt, Tahir Saygın and Karabacak, Murat and Sadioğlu Çağdaş, Öznur and Yıldırım, Reşit and Güven, Deniz Can and Akleylek, Cansu and Ediboğlu, Elif and Kutu, Muhammet Emin and Özgür, Duygu and Kardaş, Rıza Can and Bölek, Ertuğrul Çağrı and Sandal Uzun, Güllü and Özsoy, Zehra and Sarıyıldız, Emine and Ayan, Gizem and Armağan, Berkan and Erden, Abdulsamet and Kılıç, Levent and Erbasan, Funda and Alibaz-Öner, Fatma and Aşıcıoğlu, Ebru and Yazıcı, Ayten and Bilge, Nazife Şule and Küçük, Hamit and Çelik, Selda and Bes, Cemal and Akar, Servet and Yılmaz, Neslihan and Kaşifoglu, Timucin and Cefle, Ayse and Direskeneli, Haner and Yazısız, Veli and Dizdar, Ömer and Omma, Ahmet and Önen, Fatoş and Karadağ, Ömer},
  title = {Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)},
  journal = {Internal and Emergency Medicine},
  year = {2024},
  doi = {10.1007/s11739-024-03577-9}
}
Kostenlos starten →